Log In
Print
BCIQ
Print
Print this Print this
 

quizartinib (AC220)

  Manage Alerts
Collapse Summary General Information
Company Ambit Biosciences Corp.
DescriptionOral small molecule FMS-like tyrosine kinase 3 (FLT3; CD135) inhibitor
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML); Treat FLT3-internal tandem duplication (ITD)-positive acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); Treat FLT3-positive acute myelogenous leukemia (AML); Treat newly diagnosed acute myelogenous leukemia (AML); Treat relapsed or refractory acute myelogenous leukemia (AML); Treat relapsed or refractory acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL); Treat relapsed or refractory FLT3-internal tandem duplication (ITD)-positive acute myelogenous leukemia (AML)
Regulatory Designation

U.S. - Fast Track (Treat FLT3-positive acute myelogenous leukemia (AML));
U.S. - Orphan Drug (Treat FLT3-positive acute myelogenous leukemia (AML));
EU - Orphan Drug (Treat FLT3-positive acute myelogenous leukemia (AML))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today